Le Lézard
Classified in: Health
Subjects: CCA, TDS, PET

Elanco to Participate in Upcoming Investor Conferences


GREENFIELD, Ind., Feb. 22, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.

On Thursday, February 29, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2024 Animal Health Summit at 2:10 p.m. ET.

On Monday, March 4, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 10:30 a.m. ET.

On Tuesday, March 12, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference at 4:05 p.m. ET

Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will be available for approximately 30 days.

ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose? all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com

Investor Contact: Katy Grissom (317) 273-9248 [email protected]
Media Contact: Colleen Parr Dekker (317) 989-7011 [email protected]

SOURCE Elanco Animal Health


These press releases may also interest you

at 16:30
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today...

at 15:40
STEMREGEN?, the trailblazer in stem cell science-backed supplements that support the body's innate repair system, is proud to announce that they'll be returning for a second year in a row as title sponsor for the 2025 Biohacking Conference, hosted by...

at 15:00
On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for two of its products have been accepted for presentation at the 2024 American Society of...

at 14:30
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical...

at 14:25
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional...

at 13:45
Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficient Mismatched Repair Status (pMMR) TP53 Wild-Type...



News published on and distributed by: